CB1 Receptors in Human Brown Adipose Tissue (CANBAT)
Cannabinoid CB1 Receptors in Human Brown Adipose Tissue
This study investigates cannabinoid CB1 receptors in human brown adipose tissue (BAT) and other tissues using positron emission tomography (PET) imaging. Subjects will be scanned in room temperature conditions and during controlled cold exposure, and the density of CB1 receptors in BAT and other tissues will be quantified. The investigators hypothesize, that cannabinoid signaling is increased in cold conditions, when BAT is metabolically active.
Understanding the mechanisms of BAT activation and the role of endocannabinoids in humans is important and beneficial in fighting against the epidemic of obesity and diabetes.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Endocannabinoids have an important role in regulating energy balance and metabolism. Cannabinoid 1 receptors (CB1) are found in several tissues such as brown adipose tissue (BAT). Endocannabinoids and CB1 receptors participate in the control of lipid and glucose metabolism, and blockage of CB1 receptors has been found to improve metabolic factors linked to obesity and cardiovascular disease, making CB1 antagonists potential drugs against obesity and diabetes.
In this study the investigators use a PET radiotracer [18F]FMPEP-d2, which binds to CB1 receptors in vivo, to quantify the CB1 receptor density in BAT, white adipose tissue, muscle and the brain. This study is done once in warm conditions and once during controlled cold exposure. To verify whether the subject has metabolically active BAT, an additional PET scan with the radiotracer [18F]FDG is performed.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Turku, Finland, 20521
- Turku PET Centre (Turku University Hospital)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Healthy volunteer
- Group 1: BMI 20-26 kg/m2, Group2: BMI 27-40 kg/m2
Exclusion Criteria:
- BMI < 20 kg/m2or BMI > 40 kg/m2
- Any chronic disease that could affect the study outcome, including medicated type 2 diabetes
- Mental disorder or poor compliance
- Eating disorder or excessive use of alcohol, tobacco smoking or drug use
- Past dose of radiation
- Presence of any ferromagnetic objects that would make MR imaging contraindicated
- Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: [18F]FMPEP-d2 in warm conditions
PET scan is performed using PET radiotracer [18F]FMPEP-d2 in standard room temperature conditions.
|
PET radiotracer used in imaging
|
|
Annen: [18F]FMPEP-d2 in cold conditions
PET scan is performed using PET radiotracer [18F]FMPEP-d2 during controlled cold exposure.
|
PET radiotracer used in imaging
Controlled cold exposure is performed before and during PET scan
|
|
Annen: [18F]FDG in cold conditions
PET scan is performed using PET radiotracer [18F]FDG during controlled cold exposure.
|
Controlled cold exposure is performed before and during PET scan
PET radiotracer used in imaging
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
CB1 density of brown adipose tissue acquired with PET
Tidsramme: within one study day
|
PET imaging is used to quantify CB1 receptors in tissues
|
within one study day
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Glucose uptake of brown adipose tissue acquired with PET
Tidsramme: within one study day
|
PET imaging is used to quantify glucose uptake in tissues
|
within one study day
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 42/2014
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .